Aurobindo Pharma has informed that the Company has received letters from the USFDA classifying the inspections concluded at its API facilities of Unit I and XI and intermediates facility of unit IX in February 2019 as Official Action Indicated (OAI). The Company has already submitted its initial response to USFDA. The Company is sending further updates on the committed corrective actions. The Company is confident that these OAI classifications will not have an impact on disruption of supplies or the revenue from operations of these facilities.
The above information is a part of company’s filings submitted to BSE.
